Palvella Therapeutics (NASDAQ:PVLA) Research Coverage Started at Jones Trading

Jones Trading assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report released on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $45.00 price target on the stock.

PVLA has been the subject of several other research reports. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. TD Cowen initiated coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $43.50.

Palvella Therapeutics Stock Performance

PVLA opened at $27.76 on Tuesday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The business’s 50 day simple moving average is $19.95. The firm has a market cap of $311.49 million, a P/E ratio of -2.29 and a beta of 0.54.

Institutional Trading of Palvella Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Toronto Dominion Bank acquired a new position in Palvella Therapeutics during the 4th quarter worth $159,000. Frazier Life Sciences Management L.P. bought a new position in shares of Palvella Therapeutics during the fourth quarter worth about $7,847,000. Suvretta Capital Management LLC acquired a new position in Palvella Therapeutics in the fourth quarter worth about $8,574,000. DAFNA Capital Management LLC bought a new stake in Palvella Therapeutics in the fourth quarter valued at about $857,000. Finally, Cresset Asset Management LLC acquired a new stake in Palvella Therapeutics during the fourth quarter valued at approximately $251,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.